Article Information
History
- June 10, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Asghar Abdoli, PhD1,2,
- Reza Aalizadeh, MS3,*,
- Hossein Aminianfar, PhD4,
- Zahra Kianmehr, PhD5,
- Ebrahim Azimi, MS6,
- Nabbi Emamipour, PhD6,
- Hamidreza Jamshidi, PhD7,
- Mohammadreza Hosseinpour, PhD8,
- Mohammad Taqavian, PhD9 and
- Hasan Jalili, PhD10,*
- 1Pasteur Institute of Iran, Department of Hepatitis and AIDS, Tehran, Iran
- 2Amirabad Virology laboratory, Vaccine Unit, Tehran, Iran
- 3Biochemistry Department, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran
- 4Institute of Biomedical Research, University of Tehran, Tehran, Iran
- 5Department of Biochemistry, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran
- 6Department of Biotechnology, Darou Pakhsh Pharmaceutical co., Tehran, Iran
- 7Secretary of the National Headquarters for Fighting Corona Virus, Ministry of Health and Medical Education, Iran
- 8Biopharmaceutical Consultant at Pharma Engineering co, Tehran, Iran
- 9Biosunpharmed Co. Tehran, Iran
- 10Department of life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran
- ↵*Corresponding Authors
: Reza Aalizadeh, Biochemistry department, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. Email: aalizadehreza19{at}gmail.com, Hasan Jalili Bless, Department of life Science Engineering, Faculty of new sciences and technologies, University of Tehran, Tehran, Iran. Emai: Hjalili{at}ut.ac.ir
Posted June 10, 2021.
Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
